These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 33771722

  • 21. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
    Maspero JF, Nolte H, Chérrez-Ojeda I, P04139 Study Group.
    J Asthma; 2010 Dec; 47(10):1106-15. PubMed ID: 20874458
    [Abstract] [Full Text] [Related]

  • 22. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma.
    Bartels C, Jain M, Yu J, Tillmann HC, Vaidya S.
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
    [Abstract] [Full Text] [Related]

  • 23. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
    Blair HA.
    Drugs; 2021 Apr; 81(6):709-719. PubMed ID: 33871819
    [Abstract] [Full Text] [Related]

  • 24. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
    Sagara H, D'Andrea P, Tanase AM, Pethe A, Tanaka Y, Matsuo K, Hosoe M, Nakamura Y.
    J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
    [Abstract] [Full Text] [Related]

  • 25. Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents.
    McCormack PL, Plosker GL.
    Drugs; 2006 Feb; 66(8):1151-68. PubMed ID: 16789800
    [Abstract] [Full Text] [Related]

  • 26. Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study.
    Sekerel BE, Nell H, Laki I, Pak T, Contreras E, Kolarz A, D'Andrea P, Manga V, Jain M, Vaidya S, Valentin M, Sen B.
    Clin Drug Investig; 2023 Sep; 43(9):719-728. PubMed ID: 37682405
    [Abstract] [Full Text] [Related]

  • 27. Particle size and small airway effects of mometasone furoate delivered by dry powder inhaler.
    Berger R, Berger WE.
    Allergy Asthma Proc; 2013 Sep; 34(1):52-8. PubMed ID: 23406936
    [Abstract] [Full Text] [Related]

  • 28. Effects of mometasone, fluticasone, and montelukast on bone mineral density in adults with asthma.
    Maspero J, Backer V, Yao R, Staudinger H, Teper A.
    J Allergy Clin Immunol Pract; 2013 Sep; 1(6):649-55.e1. PubMed ID: 24565713
    [Abstract] [Full Text] [Related]

  • 29. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
    Kosoglou T, Hubbell J, Kantesaria B, Hanson ME, Cutler DL.
    Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
    [Abstract] [Full Text] [Related]

  • 30. Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial.
    Beier J, Watz H, Diamant Z, Hohlfeld JM, Singh D, Pinot P, Jones I, Tillmann HC.
    ERJ Open Res; 2021 Apr; 7(2):. PubMed ID: 33898609
    [Abstract] [Full Text] [Related]

  • 31. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma.
    Noonan M, Leflein J, Corren J, Staudinger H.
    BMC Pediatr; 2009 Jul 13; 9():43. PubMed ID: 19594937
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients.
    Pereira CA, Vianna FF, Cukier A, Stelmach R, Oliveira JC, Carvalho EV, Gomes EP, Mayo SV, Chibante AM, Domingues CP.
    J Bras Pneumol; 2010 Jul 13; 36(4):410-6. PubMed ID: 20835586
    [Abstract] [Full Text] [Related]

  • 33. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
    Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG.
    Chest; 2005 Jul 13; 128(1):70-7. PubMed ID: 16002918
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A, Karpel JP, Busse WW, Boulet LP, Monahan ME, Lutsky B, Staudinger H.
    Curr Med Res Opin; 2005 Aug 13; 21(8):1281-9. PubMed ID: 16083538
    [Abstract] [Full Text] [Related]

  • 35. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
    Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012 Aug 13; 7():57-71. PubMed ID: 22334769
    [Abstract] [Full Text] [Related]

  • 36. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
    Hagiwara M, Delea TE, Stanford RH.
    J Asthma; 2013 Apr 13; 50(3):287-95. PubMed ID: 23305687
    [Abstract] [Full Text] [Related]

  • 37. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.
    Kosoglou T, Cutler DL, Staudinger H, Herron JM.
    Chest; 2010 Jan 13; 137(1):115-21. PubMed ID: 19749003
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
    Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012 Jan 13; 7():73-86. PubMed ID: 22334770
    [Abstract] [Full Text] [Related]

  • 39. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
    Kosoglou T, Hubbell J, Cutler DL, Johnson-Levonas AO, Xu D, Kantesaria BS, Kim K, Miller SD.
    Chest; 2013 Dec 13; 144(6):1795-1802. PubMed ID: 24077095
    [Abstract] [Full Text] [Related]

  • 40. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.
    Skoner DP, Meltzer EO, Milgrom H, Stryszak P, Teper A, Staudinger H.
    J Asthma; 2011 Oct 13; 48(8):848-59. PubMed ID: 21854342
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.